TECHNETIUM TC 99M SESTAMIBI Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Technetium Tc 99m Sestamibi, and when can generic versions of Technetium Tc 99m Sestamibi launch?
Technetium Tc 99m Sestamibi is a drug marketed by Cardinal Health 414, Curium, Jubilant Draximage, and Sun Pharm Inds Inc. and is included in four NDAs.
The generic ingredient in TECHNETIUM TC 99M SESTAMIBI is technetium tc-99m sestamibi kit. There are four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the technetium tc-99m sestamibi kit profile page.
Summary for TECHNETIUM TC 99M SESTAMIBI
US Patents: | 0 |
Applicants: | 4 |
NDAs: | 4 |
Finished Product Suppliers / Packagers: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 10 |
Clinical Trials: | 7 |
Patent Applications: | 42 |
Formulation / Manufacturing: | see details |
DailyMed Link: | TECHNETIUM TC 99M SESTAMIBI at DailyMed |
Recent Clinical Trials for TECHNETIUM TC 99M SESTAMIBI
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Cancer Institute (NCI) | Early Phase 1 |
GE Healthcare | Early Phase 1 |
M.D. Anderson Cancer Center | Early Phase 1 |
Pharmacology for TECHNETIUM TC 99M SESTAMIBI
Drug Class | Radioactive Diagnostic Agent |
Mechanism of Action | Radiopharmaceutical Activity |